Equillium (EQ) Competitors $0.35 +0.01 (+4.42%) As of 10:58 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock EQ vs. ALGS, ABVC, ATNM, MURA, SCLX, GRCE, STTK, ITRM, ANVS, and PLURShould you be buying Equillium stock or one of its competitors? The main competitors of Equillium include Aligos Therapeutics (ALGS), ABVC BioPharma (ABVC), Actinium Pharmaceuticals (ATNM), Mural Oncology (MURA), Scilex (SCLX), Grace Therapeutics (GRCE), Shattuck Labs (STTK), Iterum Therapeutics (ITRM), Annovis Bio (ANVS), and Pluri (PLUR). These companies are all part of the "pharmaceutical products" industry. Equillium vs. Its Competitors Aligos Therapeutics ABVC BioPharma Actinium Pharmaceuticals Mural Oncology Scilex Grace Therapeutics Shattuck Labs Iterum Therapeutics Annovis Bio Pluri Aligos Therapeutics (NASDAQ:ALGS) and Equillium (NASDAQ:EQ) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, risk, institutional ownership, profitability, earnings, dividends, media sentiment and valuation. Which has more risk & volatility, ALGS or EQ? Aligos Therapeutics has a beta of 2.77, suggesting that its stock price is 177% more volatile than the S&P 500. Comparatively, Equillium has a beta of 1.86, suggesting that its stock price is 86% more volatile than the S&P 500. Which has preferable earnings & valuation, ALGS or EQ? Equillium has higher revenue and earnings than Aligos Therapeutics. Equillium is trading at a lower price-to-earnings ratio than Aligos Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAligos Therapeutics$3.27M15.95-$131.21M-$17.51-0.49Equillium$30.41M0.41-$8.07M-$0.39-0.90 Is ALGS or EQ more profitable? Equillium has a net margin of -19.62% compared to Aligos Therapeutics' net margin of -1,628.75%. Aligos Therapeutics' return on equity of 14.67% beat Equillium's return on equity.Company Net Margins Return on Equity Return on Assets Aligos Therapeutics-1,628.75% 14.67% 7.19% Equillium -19.62%-74.34%-46.75% Do analysts recommend ALGS or EQ? Aligos Therapeutics currently has a consensus price target of $70.00, indicating a potential upside of 720.63%. Equillium has a consensus price target of $3.00, indicating a potential upside of 752.27%. Given Equillium's higher probable upside, analysts clearly believe Equillium is more favorable than Aligos Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aligos Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Equillium 0 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.33 Does the media refer more to ALGS or EQ? In the previous week, Aligos Therapeutics' average media sentiment score of 0.00 equaled Equillium'saverage media sentiment score. Company Overall Sentiment Aligos Therapeutics Neutral Equillium Neutral Do institutionals and insiders believe in ALGS or EQ? 60.4% of Aligos Therapeutics shares are owned by institutional investors. Comparatively, 27.0% of Equillium shares are owned by institutional investors. 4.8% of Aligos Therapeutics shares are owned by insiders. Comparatively, 31.6% of Equillium shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. SummaryAligos Therapeutics beats Equillium on 7 of the 13 factors compared between the two stocks. Get Equillium News Delivered to You Automatically Sign up to receive the latest news and ratings for EQ and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding EQ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EQ vs. The Competition Export to ExcelMetricEquilliumMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$12.18M$2.95B$5.55B$8.99BDividend YieldN/A2.44%5.25%4.03%P/E Ratio-0.8721.1327.4420.13Price / Sales0.41255.12414.93172.83Price / CashN/A41.8337.0657.97Price / Book0.657.848.135.61Net Income-$8.07M-$54.96M$3.16B$248.50M7 Day Performance7.65%4.54%2.92%4.36%1 Month Performance0.40%2.98%3.14%6.87%1 Year Performance-51.91%5.19%33.91%20.78% Equillium Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EQEquillium1.8113 of 5 stars$0.35+4.4%$3.00+752.3%-52.5%$12.18M$30.41M-0.8740Gap DownALGSAligos Therapeutics3.7586 of 5 stars$7.21flat$70.00+870.9%-26.7%$44.08M$3.94M-0.4190ABVCABVC BioPharma0.4832 of 5 stars$2.22-14.3%N/A+513.6%$43.98M$508.38K-17.0830High Trading VolumeATNMActinium Pharmaceuticals3.0243 of 5 stars$1.40-1.4%$4.00+185.7%N/A$43.67M$81K-1.0130Positive NewsMURAMural Oncology3.0917 of 5 stars$2.47-0.4%$12.00+385.8%-14.7%$42.83MN/A-0.32119SCLXScilex1.5481 of 5 stars$5.89-2.6%$455.00+7,625.0%-89.8%$42.06M$56.59M-0.2080GRCEGrace Therapeutics1.7558 of 5 stars$2.97flat$12.00+304.0%N/A$41.07MN/A-3.34N/ASTTKShattuck Labs3.0035 of 5 stars$0.79-7.3%$7.50+847.2%-77.8%$40.89M$5.72M-0.57100Gap UpITRMIterum Therapeutics1.9126 of 5 stars$1.00-1.5%$9.00+804.5%-21.5%$40.40MN/A-1.0110ANVSAnnovis Bio1.6444 of 5 stars$2.18+6.3%$30.25+1,287.6%-81.4%$39.95MN/A-1.013PLURPluri3.5022 of 5 stars$4.95-2.8%$12.00+142.4%-5.0%$39.87M$330K-0.90150News Coverage Related Companies and Tools Related Companies Aligos Therapeutics Competitors ABVC BioPharma Competitors Actinium Pharmaceuticals Competitors Mural Oncology Competitors Scilex Competitors Grace Therapeutics Competitors Shattuck Labs Competitors Iterum Therapeutics Competitors Annovis Bio Competitors Pluri Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:EQ) was last updated on 7/10/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredHow a Kansas farm boy gained 1,285% in two daysA former farm kid placed a simple trade… and cashed out a 1,285% gain two days later. It wasn’t crypto or a...TradeSmith | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting—or plan to collect—Social Security, this could be a game-changer. A new initiative tie...InvestorPlace | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Equillium, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Equillium With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
